Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

Cancer Patients Respond Poorly to First COVID mRNA Vax Dose

The data, concluded in a report posted to the preprint server medRxiv, support prioritization of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine, as barely one-quarter of patients with cancer obtained protection (28% immune efficacy rate, including 13% in patients with blood cancers) against COVID-19 after one dose of the Pfizer/BioNTech vaccine.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Epoch Health
Healthgrades for Professionals
MDLinx
Neurology Advisor
Oncology Learning Network
Oncology News Central (ONC)
Psych Congress Network
Psychiatrist.com
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form